Evidence map›Paper›PMID 24030421›Full record

ArticleCirculation2013

Tetrahydrobiopterin determines vascular remodeling through enhanced endothelial cell survival and regeneration.

Ziad A Ali, Ruth Rinze, Gillian Douglas, Yanhua Hu, Qingzhong Xiao, Wei Qi, Eileen McNeill, Christina Bursill, Isaac George, David R Greaves and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Circulation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Role of Outer Membrane Vesicles FromFrontiers in cell and developmental biology · 2021
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Redox regulation of vascular remodeling.Cellular and molecular life sciences : CMLS · 2016
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Ziad A Ali *Center for Interventional Vascular Therapy, Division of Cardiology, New York Presbyterian Hospital and Columbia University, New York, NY; Cardiovascular Research Foundation, New York, NY; Department of Cardiovascular Medicine, John Radcliffe Hospital and University of Oxford, Oxford, United Kingdom.
Ruth Rinze *Department of Cardiovascular Medicine, John Radcliffe Hospital and University of Oxford, Oxford, United Kingdom.
Gillian DouglasDepartment of Cardiovascular Medicine, John Radcliffe Hospital and University of Oxford, Oxford, United Kingdom.
Yanhua HuCardiovascular Division, King's College Hospital, London, United Kingdom.
Qingzhong XiaoCardiovascular Division, King's College Hospital, London, United Kingdom.
Wei QiCenter for Interventional Vascular Therapy, Division of Cardiology, New York Presbyterian Hospital and Columbia University, New York, NY.
Eileen McNeillDepartment of Cardiovascular Medicine, John Radcliffe Hospital and University of Oxford, Oxford, United Kingdom.
Christina BursillDepartment of Cardiovascular Medicine, John Radcliffe Hospital and University of Oxford, Oxford, United Kingdom.
Isaac GeorgeCenter for Interventional Vascular Therapy, Division of Cardiology, New York Presbyterian Hospital and Columbia University, New York, NY.
David R GreavesSir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
Qingbo XuCardiovascular Division, King's College Hospital, London, United Kingdom.
Keith M ChannonDepartment of Cardiovascular Medicine, John Radcliffe Hospital and University of Oxford, Oxford, United Kingdom.
King's College Hospital · GBCardiovascular Research Foundation · USNewYork–Presbyterian Hospital · USUniversity of Oxford · GBJohn Radcliffe Hospital · GB

Funding

British Heart Foundation FS/07/050/23514British Heart Foundation FS/09/044/28007British Heart Foundation PG/05/076/19124British Heart Foundation PG/06/158/22078British Heart Foundation PG/11/40/28891British Heart Foundation RG/07/003/23133British Heart Foundation RG/09/004/27647British Heart Foundation RG/10/15/28578British Heart Foundation RG/12/5/29576Department of Health IS-BRC-0211-10025Wellcome Trust 073213/Z/03/ZWellcome Trust 090532
6 · The paper itself

Abstract

backgroundEndothelial cell (EC) survival and regeneration are important determinants of the response to vascular injury that leads to neointimal hyperplasia and accelerated atherosclerosis. Nitric oxide (NO) is a key regulator of EC and endothelial progenitor cell function, but the pathophysiological mechanisms that regulate endothelial NO synthase in endothelial regeneration remain unclear. METHODS AND

resultsEndothelium-targeted overexpression of GTP cyclohydrolase (GCH) I increased levels of the endothelial NO synthase cofactor, tetrahydrobiopterin, in an EC-specific manner and reduced neointimal hyperplasia in experimental vein grafts in GCH/apolipoprotein E-knockout mice. These effects were mediated through enhanced donor-derived survival and recipient-derived repopulation of GCH transgenic ECs, revealed by tracking studies in Tie2-LacZ/GCH-Tg/apolipoprotein E-knockout recipient mice or donor grafts, respectively. Endothelial GCH overexpression increased endothelial NO synthase coupling and enhanced the proliferative capacity of ECs and circulating endothelial progenitor cell numbers after vascular injury.

conclusionsThese observations indicate that endothelial tetrahydrobiopterin availability modulates neointimal hyperplasia after vascular injury via accelerated EC repopulation and growth. Targeting tetrahydrobiopterin-dependent endothelial NO synthase regulation in the endothelium is a rational therapeutic target to enhance endothelial regeneration and reduce neointimal hyperplasia in vascular injury states.

Indexed as

AnimalsBiopterinsCell SurvivalEndothelial CellsHumansHyperplasiaMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicNeointimaRegenerationTransplantsUp-RegulationVena Cava, InferiorBiopterinssapropterinendothelial cellsendothelial progenitor cellsfree radicalsnitric oxide synthaseremodeling

Identifiers

PMID24030421
PMCPMC5357046
OpenAlexW2084642457

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.